NCT01395758View on ClinicalTrials.gov

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
DRUG

ARQ 197 plus erlotinib

Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.

DRUG

Pemetrexed, docetaxel or gemcitabine

Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.

Trial Locations (13)

10016

New York

15232

Pittsburgh

20057

Washington D.C.

21205

Baltimore

29425

Charleston

30341

Atlanta

33331

Weston

60611

Chicago

66160

Kansas City

75390

Dallas

94305

Stanford

02114

Boston

01805

Burlington

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT01395758 - Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter